Read by QxMD icon Read


Warren Chow, Paul Frankel, Chris Ruel, Dejka M Araujo, Mohammed Milhem, Scott Okuno, Lee Hartner, Samir Undevia, Arthur Staddon
BACKGROUND: This single-arm, multicenter, phase 2 study evaluated the safety and antitumor activity of pazopanib in patients with unresectable or metastatic conventional chondrosarcoma. METHODS: Eligible patients had conventional chondrosarcoma of any grade with measurable tumors that were unresectable or metastatic. Patients with mesenchymal, dedifferentiated, and extraskeletal myxoid chondrosarcoma subtypes and patients who received prior tyrosine kinase inhibitor therapy were excluded...
September 11, 2019: Cancer
Ajay Major, Derek E Smith, Debashis Ghosh, Rachel Rabinovitch, Manali Kamdar
BACKGROUND: Previous studies have shown an increased risk of secondary primary malignancies (SPMs) after diffuse large B-cell lymphoma (DLBCL) treatment. Whether stage of DLBCL at diagnosis affects the subtypes of SPMs that occur has not been previously described. METHODS: The Surveillance, Epidemiology, and End Results database was queried for patients aged >18 years diagnosed with primary DLBCL from 1973 to 2010 and categorized by early stage (ES) (stage I-II) or advanced stage (AS) (stage III-IV) disease...
September 11, 2019: Cancer
Eiji Iwama, Kazuko Sakai, Noriko Hidaka, Koji Inoue, Akiko Fujii, Noriaki Nakagaki, Keiichi Ota, Ryo Toyozawa, Koichi Azuma, Keita Nakatomi, Taishi Harada, Junko Hisasue, Shinya Sakata, Takayuki Shimose, Junji Kishimoto, Yoichi Nakanishi, Kazuto Nishio, Isamu Okamoto
BACKGROUND: The aim of this study was to evaluate the potential of liquid biopsy for prediction of the efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatment and for assessment of the changes in genetic alterations during such treatment. METHODS: Plasma samples were prospectively collected from non-small cell lung cancer patients with EGFR-activating mutations during EGFR-TKI treatment until disease progression and were analyzed for such mutations with droplet digital polymerase chain reaction and for other somatic alterations with next-generation sequencing...
September 10, 2019: Cancer
Patricia A Valverde, Linda Burhansstipanov, Steven Patierno, Sharon Gentry, Andrea Dwyer, Karla L Wysocki, Angela K Patterson, Linda U Krebs, Jean Sellers, Danelle Johnston
No abstract text is available yet for this article.
September 10, 2019: Cancer
Patricia Mae G Santos, Andrew R Barsky, Wei-Ting Hwang, Curtiland Deville, Xingmei Wang, Stefan Both, Justin E Bekelman, John P Christodouleas, Neha Vapiwala
BACKGROUND: Despite increasing utilization of proton-beam therapy (PBT) in the postprostatectomy setting, no data exist regarding toxicity outcomes relative to intensity-modulated radiotherapy (IMRT). The authors compared acute and late genitourinary (GU) and gastrointestinal (GI) toxicity outcomes in patients with prostate cancer (PC) who received treatment with postprostatectomy IMRT versus PBT. METHODS: With institutional review board approval, patients with PC who received adjuvant or salvage IMRT or PBT (70...
September 10, 2019: Cancer
Shidan Wang, Sunny Lai, Mitchell S von Itzstein, Lin Yang, Donghan M Yang, Xiaowei Zhan, Guanghua Xiao, Ethan A Halm, David E Gerber, Yang Xie
BACKGROUND: With the expansion of non-small cell lung cancer (NSCLC) screening methods, the percentage of cases with early-stage NSCLC is anticipated to increase. Yet it remains unclear how the type and case volume of the health care facility at which treatment occurs may affect surgery selection and overall survival for cases with early-stage NSCLC. METHODS: A total of 332,175 cases with the American Joint Committee on Cancer (AJCC) TNM stage I and stage II NSCLC who were reported to the National Cancer Data Base (NCDB) by 1302 facilities were studied...
September 10, 2019: Cancer
Melissa Mazor, Steven M Paul, Margaret A Chesney, Lee-May Chen, Betty Smoot, Kimberly Topp, Yvette P Conley, Jon D Levine, Christine Miaskowski
BACKGROUND: Although multiple co-occurring symptoms are a significant problem for cancer survivors, to the authors' knowledge little is known regarding the phenotypic characteristics associated with a higher symptom burden. The objectives of the current study were to evaluate the occurrence, severity, and distress associated with 32 symptoms and examine the phenotypic and stress characteristics associated with a higher symptom burden. METHODS: A total of 623 cancer survivors completed a demographic questionnaire, as well as measures of functional status, comorbidity, and global (Perceived Stress Scale) and cancer-related (Impact of Event Scale-Revised) stress...
September 10, 2019: Cancer
Robin L Jones, Robert G Maki, Shreyaskumar R Patel, George Wang, Tracy A McGowan, Waleed S Shalaby, Roland E Knoblauch, Margaret von Mehren, George D Demetri
BACKGROUND: The results of the randomized, phase 3 ET743-SAR-3007 trial demonstrated that trabectedin had a significantly longer progression-free survival (PFS) compared with dacarbazine in patients with advanced leiomyosarcoma/liposarcoma after the failure of prior chemotherapy. Patients randomized to trabectedin received a 24-hour intravenous infusion either in an inpatient or outpatient setting. Herein, the authors reported the safety, efficacy, and patient-reported outcomes based on first infusion site of care...
September 10, 2019: Cancer
W Robert Lee
No abstract text is available yet for this article.
September 10, 2019: Cancer
Jeremy S Abramson, Kelly E Irwin, Matthew J Frigault, Jorg Dietrich, Brianne McGree, Justin T Jordan, Andrew J Yee, Yi-Bin Chen, Noopur S Raje, Jeffrey A Barnes, Benjamin Davis
No abstract text is available yet for this article.
September 10, 2019: Cancer
Michael Behring, Kevin Hale, Bunyamin Ozaydin, William E Grizzle, Stephen O Sodeke, Upender Manne
BACKGROUND: Although general trends in cancer outcomes are improving, racial/ethnic disparities in patient outcomes continue to widen, suggesting disparity-related shortcomings in cancer research designs. METHODS: Using convenience sampling, a total of 24 data sources, representing several research designs and 5 high-burden tumor types, were included for analyses. The percentages of races/ethnicities across each design/tumor type were compared with those of the 2017 US Census data...
September 10, 2019: Cancer
Nivaldo B de Pinho, Renata B Martucci, Viviane D Rodrigues, Cristiane A D'Almeida, Luiz C S Thuler, Claudia Saunders, Harriet Jager-Wittenaar, Wilza A F Peres
BACKGROUND: Malnutrition in cancer is an independent factor associated with negative clinical outcomes. The objective of this study was to evaluate the prevalence of malnutrition across different age groups in patients with cancer in Brazil and to identify associations with nutrition impact symptoms (NIS). METHODS: In this observational, cross-sectional, multicenter study, the authors evaluated 4783 patients with cancer aged ≥20 years who were admitted to 45 public hospitals in Brazil...
September 9, 2019: Cancer
Jessica L Petrick, Nan Li, Lesley A Anderson, Leslie Bernstein, Douglas A Corley, Hashem B El Serag, Sheetal Hardikar, Linda M Liao, Geoffrey Liu, Liam J Murray, Joel H Rubenstein, Jennifer L Schneider, Nicholas J Shaheen, Aaron P Thrift, Piet A van den Brandt, Thomas L Vaughan, David C Whiteman, Anna H Wu, Wei K Zhao, Marilie D Gammon, Michael B Cook
BACKGROUND: Diabetes is positively associated with various cancers, but its relationship with tumors of the esophagus/esophagogastric junction remains unclear. METHODS: Data were harmonized across 13 studies in the International Barrett's and Esophageal Adenocarcinoma Consortium, comprising 2309 esophageal adenocarcinoma (EA) cases, 1938 esophagogastric junction adenocarcinoma (EGJA) cases, 1728 Barrett's esophagus (BE) cases, and 16,354 controls. Logistic regression was used to estimate study-specific odds ratios (ORs) and 95% CIs for self-reported diabetes in association with EA, EGJA, and BE...
September 6, 2019: Cancer
Anne L Versteeg, Arjun Sahgal, Norio Kawahara, Laurence D Rhines, Daniel M Sciubba, Michael H Weber, Áron Lazary, Michael G Fehlings, James M Schuster, Michelle J Clarke, Paul M Arnold, Stefano Boriani, Chetan Bettegowda, Ziya L Gokaslan, Charles G Fisher
BACKGROUND: Patient satisfaction is infrequently investigated despite its importance in assessing efficacy and patient comprehension. The purpose of this study was to investigate patient satisfaction with treatment outcomes after surgery and/or radiotherapy for spinal metastases and to evaluate how health-related quality of life (HRQOL) is related to patient satisfaction. METHODS: Patients with spinal metastases treated with surgery and/or radiotherapy were enrolled in a prospective, international, observational study...
September 6, 2019: Cancer
Mudit Chowdhary, Akansha Chowdhary, Neilayan Sen, Nicholas G Zaorsky, Kirtesh R Patel, Dian Wang
BACKGROUND: The role of chemotherapy in extremity/trunk soft-tissue sarcoma (ET-STS) is controversial, even for patients at high risk for distant recurrence and death (those with high-grade tumors ≥5 cm in size). This study examines the impact of integrating chemotherapy with neoadjuvant radiotherapy (RT) on overall survival (OS) for patients with high-risk ET-STS. METHODS: The National Cancer Data Base was queried for adult patients with high-risk ET-STS who received neoadjuvant RT and limb salvage surgery between 2006 and 2014...
September 6, 2019: Cancer
Celestia S Higano, Andrew J Armstrong, A Oliver Sartor, Nicholas J Vogelzang, Philip W Kantoff, David G McLeod, Christopher M Pieczonka, David F Penson, Neal D Shore, Jeffrey Vacirca, Raoul S Concepcion, Ronald F Tutrone, Luke T Nordquist, David I Quinn, Vahan Kassabian, Mark C Scholz, Matt Harmon, Robert C Tyler, Nancy N Chang, Hong Tang, Matthew R Cooperberg
BACKGROUND: The large registry, PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data (PROCEED)(NCT01306890), evaluated sipuleucel-T immunotherapy for asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). METHODS: PROCEED enrolled patients with mCRPC receiving 3 biweekly sipuleucel-T infusions. Assessments included overall survival (OS), serious adverse events (SAEs), cerebrovascular events (CVEs), and anticancer interventions (ACIs)...
September 4, 2019: Cancer
Amer M Zeidan, Nikolai A Podoltsev, Xiaoyi Wang, Jan Philipp Bewersdorf, Rory M Shallis, Scott F Huntington, Steven D Gore, Amy J Davidoff, Xiaomei Ma, Rong Wang
BACKGROUND: The majority of patients with acute myeloid leukemia (AML) are aged >65 years at the time of diagnosis and are not actively treated. The objective of the current study was to determine the prevalence, temporal trends, and factors associated with no active treatment (NAT) among older patients with AML in the United States. METHODS: A retrospective analysis was performed of Surveillance, Epidemiology, and End Results (SEER)-Medicare data from 14,089 patients with AML residing in the United States who were diagnosed with AML at age ≥66 years during 2001 through 2013...
September 4, 2019: Cancer
Balambal Bharti, Folasade Fola Popoola May, Jesse Nodora, Maria Elena Martinez, Karina Moyano, Shauntay L Davis, Christian B Ramers, Felipe Garcia-Bigley, Shawne O'Connell, Kevin Ronan, Melissa Barajas, Sheree Gordon, Giselle Diaz, Evelyn Ceja, Meghan Powers, Elva M Arredondo, Samir Gupta
BACKGROUND: The effectiveness of colorectal cancer screening with fecal immunochemical tests (FITs) of stool blood depends on high rates of colonoscopy follow-up for abnormal FITs and the use of high-quality tests. This study characterized colonoscopy referral and completion among patients with abnormal FITs and the types of FITs implemented in a sample of Southern California Federally Qualified Health Centers (FQHCs). METHODS: FQHCs in San Diego, Imperial, and Los Angeles Counties were invited to define a cohort of ≥150 consecutive patients with abnormal FITs in 2015-2016 and to provide data on sex, insurance status, diagnostic colonoscopy referrals and completion within 6 months of abnormal FITs, and the types (brands) of FITs implemented...
September 3, 2019: Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"